Jesús
Corral Jaime
Ikertzailea 2022-(e)ra arte
Eli Lilly and Company
Indianapolis, EE. UU.Eli Lilly and Company-ko ikertzaileekin lankidetzan egindako argitalpenak (4)
2014
-
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately after Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Clinical Lung Cancer, Vol. 15, Núm. 6, pp. 418-425
2013
-
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Journal of Clinical Oncology, Vol. 31, Núm. 23, pp. 2895-2902
2012
-
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial
The Lancet Oncology, Vol. 13, Núm. 3, pp. 247-255
-
Safety, resource use, and quality of life in paramount: A phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Journal of Thoracic Oncology, Vol. 7, Núm. 11, pp. 1713-1721